Survival of Civilian and Prisoner Drug-Sensitive, Multiand Extensive Drug- Resistant Tuberculosis Cohorts Prospectively Followed in Russia

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Balabanova, Yanina ^a,b   Nikolayevskyy, Vladyslav ^a   Ignatyeva, Olga ^b   Kontsevaya, Irina ^b   Rutterford, Clare M ^a   Shakhmistova, Anastasiya ^b   Malomanova, Nadezhda ^b   Chinkova, Yulia ^b   Mironova, Svetlana ^b   Fedorin, Ivan ^b   Drobniewski, Francis A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Samara Oblast Tuberculosis Dispensary   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ISONIAZID; KATG PROTEIN; PROTEIN INHA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL GENE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INHA GENE; KATG GENE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; NONHUMAN; PRISONER; PROSPECTIVE STUDY; RISK FACTOR; RPOB GENE; RUSSIAN FEDERATION; SEQUENCE ANALYSIS; SURVIVAL TIME; DEMOGRAPHY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODEL; STATISTICS; TIME;

ADULT; DEMOGRAPHY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PRISONERS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; RUSSIA; TIME FACTORS;

EID: 79958703433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020531     Document Type: Article

References (39)

1. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, et al. (2008) Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178: 1075-1082.
2. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, et al. (2008) Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 300: 2153-2160.
3. Jeon DS, Kim DH, Kang HS, Hwang SH, Min JH, et al. (2009) Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 13: 594-600.
4. He GX, Xie YG, Wang LX, Borgdorff MW, van der Werf MJ, et al. (2010) Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS One 5: e10799.
5. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, et al. (2008) Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin Infect Dis 46: 958-959.
6. Bendayan D, Hendler A, Polansky V, Weinberger M, (2010) Outcome of hospitalized MDR-TB patients: Israel 2000-2005. Eur J Clin Microbiol Infect Dis.
7. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, et al. (2010) Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375: 1814-1829.
8. Koenig R, (2008) Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319: 894-897.
9. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
10. Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Facchini A, et al. (2009) MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J 34: 778-779.
11. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, et al. (2007) HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 (Suppl 1): S86-107.
12. Migliori GB, Centis R, Lange C, Richardson MD, Sotgiu G, (2009) Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Curr Opin Pulm Med 16: 171-179.
13. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, et al. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373: 1861-1873.
14. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, et al. (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 36: 584-593.
15. (2010) Samara AIDS Center Epidemiological Update. http://wwwnoaidsru/r/11/ Accessed: 31.01.2011.
16. Samara Oblast Tuberculosis Dispensary (2009) Annual Report on TB Control in Samara Oblast.
17. Balabanova Y, Ruddy M, Hubb J, Yates M, Malomanova N, et al. (2005) Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 24: 136-139.
18. Ministry of Health of the Russian Federation P Prikaz of the Ministry of Health of the Russian Federation # 109 from 21 March 2003 "On improvement of TB control activities in the Russian Federation".
19. Siddiqi S, Rusch-Gerdes S, Alexander H, Drobniewski F, Feldman K, (2007) MGIT Procedure Manual. For BACTEC™ MGIT 960™ TB System (Also applicable for Manual MGIT) Mycobacteria Growth Indicator Tube (MGIT) Culture and Drug Susceptibility Demonstration Projects.
20. Kruuner A, Yates MD, Drobniewski FA, (2006) Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 44: 811-818.
21. World Health Organization (2008) Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva WHO/HTM/TB/2008392.
22. Brown TJ, Herrera-Leon L, Anthony RM, Drobniewski FA, (2006) The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J Microbiol Methods 65: 294-300.
23. Nikolayevskyy VV, Brown TJ, Bazhora YI, Asmolov AA, Balabanova YM, et al. (2007) Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect 13: 129-138.
24. Drobniewski F, Balabanova Y, Nikolayevsky V, Ruddy M, Kuznetzov S, et al. (2005) Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 293: 2726-2731.
25. Velji P, Nikolayevskyy V, Brown T, Drobniewski F, (2009) Discriminatory ability of hypervariable variable number tandem repeat loci in population-based analysis of Mycobacterium tuberculosis strains, London, UK. Emerg Infect Dis 15: 1609-1616.
26. Kwara A, Schiro R, Cowan LS, Hyslop NE, Wiser MF, et al. (2003) Evaluation of the epidemiologic utility of secondary typing methods for differentiation of Mycobacterium tuberculosis isolates. J Clin Microbiol 41: 2683-2685.
27. Nikolayevskyy V, Gopaul K, Balabanova Y, Brown T, Fedorin I, et al. (2006) Differentiation of tuberculosis strains in a population with mainly Beijing-family strains. Emerg Infect Dis 12: 1406-1413.
28. Gopaul KK, Brown TJ, Gibson AL, Yates MD, Drobniewski FA, (2006) Progression toward an improved DNA amplification-based typing technique in the study of Mycobacterium tuberculosis epidemiology. J Clin Microbiol 44: 2492-2498.
29. Balabanova Y, Drobniewski F, Fedorin I, Zakharova S, Nikolayevskyy V, et al. (2006) The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation. Respir Res 7: 44.
30. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P, (1999) Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 159: 733-740.
31. Atun RA, Samyshkin YA, Drobniewski F, Kuznetsov SI, Fedorin IM, et al. (2005) Seasonal variation and hospital utilization for tuberculosis in Russia: hospitals as social care institutions. Eur J Public Health 15: 350-354.
32. Drobniewski F, (1995) Tuberculosis in prisons--forgotten plague. Lancet 346: 948-949.
33. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, et al. (2005) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 60: 130-135.
34. World Health Organization (2008) Global tuberculosis control: surveillance, planning, financing. Geneva WHO/HTM/TB/2008.393.
35. Balabanova Y, Fedorin I, Kuznetsov S, Graham C, Ruddy M, et al. (2004) Antimicrobial prescribing patterns for respiratory diseases including tuberculosis in Russia: a possible role in drug resistance? J Antimicrob Chemother 54: 673-679.
36. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. (2009) HIV Co-infection in Multidrug- and Extensively Drug-resistant Tuberculosis Results in High Early Mortality. Am J Respir Crit Care Med.
37. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, et al. (2009) Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 23: 2485-2495.
38. Dheda K, Warren RM, Zumla A, Grobusch MP, (2010) Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 24: 705-725.
39. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563-574.